Who is sponsoring NCT06245798?

NCT06245798 is sponsored by Tang-Du Hospital.

What drugs are being tested in NCT06245798?

Interventions in NCT06245798: transarterial chemoembolisation.

What condition does NCT06245798 study?

NCT06245798 studies Hepatic Carcinoma.

Is NCT06245798 still recruiting?

NCT06245798 is currently completed. Last updated 7 February 2024.

Last reviewed 2024-02-07 · How we verify

NCT06245798

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension

Completed Last updated 7 February 2024

What this trial tests

trial testing transarterial chemoembolisation in Hepatic Carcinoma in 3,000 participants. Completed in 1 December 2023.

Timeline

1 January 2023

Primary endpoint
1 April 2023

1 December 2023

Quick facts

Lead sponsor	Tang-Du Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	3,000
Start date	1 January 2023
Primary completion	1 April 2023
Estimated completion	1 December 2023
Sites	2 locations across China

Drugs / interventions tested

transarterial chemoembolisation — full drug profile →

Conditions studied

Hepatic Carcinoma — all drugs for Hepatic Carcinoma →

Sponsor

Tang-Du Hospital

Who can join

18 and older, any sex, with Hepatic Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Clinically significant portal hypertension limits the therapeutic options for hepatocellular carcinoma (HCC), which is closely associated with patient prognosis. HCC patients with CPSH are heterogeneous and treatment allocation remains controversial. The aim of this study was to compare the survival benefits of liver resection (LR) and transarterial chemoembolisation (TACE) in these populations.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians.
Moris D, Martinino A, Schiltz S, Allen PJ, et al · · 2025 · cited 38× · PMID 40392748 · DOI 10.3322/caac.70018

Verify or expand the search:

Other trials of transarterial chemoembolisation

Trials testing the same drug.

NCT06245785 — Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver Function · completed

Other recruiting trials for Hepatic Carcinoma

Currently open trials in the same condition.

NCT07359586 — Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia · recruiting
NCT06342414 — An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer · recruiting
NCT04220944 — Combined Locoregional Treatment With Immunotherapy for Unresectable HCC. · Phase 1 · active not recruiting

Other Tang-Du Hospital trials

Trials by the same sponsor.

NCT07528235 — An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intraven · Phase 1 · not yet recruiting
NCT07516522 — Intra-arterial Methylprednisolone After Endovascular Thrombectomy · Phase 2 · recruiting
NCT07354061 — Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC) · Phase 1, PHASE2 · recruiting
NCT07327736 — Anesthesia Comparison in Early-stage Small NSCLC: A Multicenter RCT · NA · not yet recruiting
NCT07452601 — Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06245798 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tang-Du Hospital
Last refreshed: 7 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06245798.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing